Bay Colony Advisory Group Inc d b a Bay Colony Advisors Buys Shares of 12,500 Recursion Pharmaceuticals, Inc. $RXRX

Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,500 shares of the company’s stock, valued at approximately $63,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in shares of Recursion Pharmaceuticals by 135.3% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 911,085 shares of the company’s stock valued at $4,610,000 after purchasing an additional 523,848 shares in the last quarter. Rossby Financial LCC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter valued at about $142,000. Teacher Retirement System of Texas raised its stake in shares of Recursion Pharmaceuticals by 18.6% during the second quarter. Teacher Retirement System of Texas now owns 79,567 shares of the company’s stock valued at $403,000 after purchasing an additional 12,452 shares in the last quarter. Brighton Jones LLC raised its stake in shares of Recursion Pharmaceuticals by 38.6% during the second quarter. Brighton Jones LLC now owns 29,309 shares of the company’s stock valued at $148,000 after purchasing an additional 8,156 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Recursion Pharmaceuticals by 97.2% during the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after purchasing an additional 4,446 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.43% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average target price of $7.25.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $5.52 on Monday. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -3.10 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The business has a 50 day moving average price of $5.26 and a two-hundred day moving average price of $5.21.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.40) earnings per share. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.